IRD
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Opus Genetics receives FDA approval for phentolamine ophthalmic solution 0.75% to treat presbyopiaOct 16, 2026
- Opus Genetics presents positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026Oct 15, 2026
- Opus Genetics reported positive low-dose Cohort 1 results from the Phase 1/2 OPGx-BEST1 trial and completed a successful FDA Type C meeting supporting potential Phase 3 dosing in 2027Sep 9, 2026
- Opus Genetics completed patient enrollment in the registrational Phase 3 trial of OPGx-LCA5Aug 3, 2026
- Opus Genetics provided an update and timeline for the OPGx-BEST1 programJul 9, 2026